Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.

Elsada A, Pearce F, George E, Adler A.

Lancet Oncol. 2014 Sep;15(10):1058-9. No abstract available.

PMID:
25328938
2.

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.

Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S, Mavranezouli I, Wonderling D, Alderson P, Ruiz F.

Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580.

3.

External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy.

Dell'Oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, Shariat S, Montorsi F, Briganti A.

J Endourol. 2014 Apr;28(4):416-23. doi: 10.1089/end.2013.0571. Epub 2014 Jan 9.

PMID:
24188052
5.

Androgen deprivation treatment in prostate cancer.

Thomas BC, Neal DE.

BMJ. 2013 Jan 8;346:e8555. doi: 10.1136/bmj.e8555. No abstract available.

PMID:
23303885
6.

Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.

Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC.

Ann Oncol. 2013 May;24(5):1338-43. doi: 10.1093/annonc/mds618. Epub 2012 Dec 30.

7.

NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Dyer M, Rinaldi F, George E, Adler AI.

Lancet Oncol. 2012 Aug;13(8):762-3. No abstract available.

PMID:
23024987
8.

[Screening--balancing between advantages and disadvantages].

Hugosson J, Carlsson S.

Lakartidningen. 2012 Feb 22-28;109(8):398-402. Review. Swedish. No abstract available.

PMID:
22509664
9.

Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.

Peppercorn J, Armstrong A, Zaas DW, George D.

Urol Oncol. 2013 Oct;31(7):1079-84. doi: 10.1016/j.urolonc.2011.12.022. Epub 2012 Feb 4.

PMID:
22305627
10.

Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.

Bynum J, Song Y, Fisher E.

J Am Geriatr Soc. 2010 Apr;58(4):674-80. doi: 10.1111/j.1532-5415.2010.02761.x. Epub 2010 Mar 22.

11.

Screening for prostate cancer.

Lee TH, Kantoff PW, McNaughton-Collins MF.

N Engl J Med. 2009 Mar 26;360(13):e18. doi: 10.1056/NEJMp0901825. Epub 2009 Mar 18. No abstract available.

12.

Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.

Reynolds TM.

J Tissue Viability. 2008 Nov;17(4):115-20. doi: 10.1016/j.jtv.2007.09.005. Epub 2008 Feb 20. Review.

PMID:
19061825
13.

[NPT (near patient test) in the pharmacy: document and practice guidelines 2008].

Stuard S, Cesarone MR, Belcaro G, Ledda A, Cornelli U, Di Renzo A, Grossi MG, Pellegrini L, Gizzi G, Vinciguerra G, Dugall M, Corsi M, Ippolito E, Di Palma T, Zulli C, Del Boccio G.

Minerva Cardioangiol. 2008 Oct;56(5 Suppl):11-20. Italian.

PMID:
19597405
15.

Costs of radiotherapy.

Norlund A; SBU Survey Group.

Acta Oncol. 2003;42(5-6):411-5.

PMID:
14596503
16.

Routine prostate screening may be unnecessary and harmful.

Levenson D.

Rep Med Guidel Outcomes Res. 2003 Jan 10;14(1):5-7. No abstract available.

PMID:
12762303
17.

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.

Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG.

Ann Intern Med. 1997 Mar 15;126(6):468-79.

PMID:
9072935
18.
19.

PSA guidelines disputed by physician with personal experience.

Tieszen RL.

Geriatrics. 1994 Nov;49(11):11-2. No abstract available.

PMID:
7525415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk